Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020)

First Author: Ramasamy M

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32466-1

Publication URI: http://dx.doi.org/10.1016/s0140-6736(20)32466-1

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 10267